DTaP5-IPV-Hib-HepB administered concomitantly with PCV7 or 1 month apart at 15 months of age following the infant series was well-tolerated and elicited antibody responses to all vaccine antigens , with no significant interference from concomitant PCV7 administration ( clinicaltrials.gov registration number NCT00362427 ) .